A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China.

MLA

Jiang, Yanqing, et al. “A Cost-Effectiveness Analysis of IGlarLixi Versus IDegAsp and Appropriate Price Exploration of IGlarLixi for Type 2 Diabetes Mellitus Patients in China.” Clinical Drug Investigation, vol. 43, no. 4, Apr. 2023, pp. 251–63. EBSCOhost, https://doi.org/10.1007/s40261-023-01255-w.

APA

Jiang, Y., Liu, R., Xuan, J., Lin, S., Zheng, Q., & Pang, J. (2023). A Cost-effectiveness Analysis of iGlarLixi Versus IDegAsp and Appropriate Price Exploration of iGlarLixi for Type 2 Diabetes Mellitus Patients in China. Clinical Drug Investigation, 43(4), 251–263. https://doi.org/10.1007/s40261-023-01255-w

Chicago

Jiang, Yanqing, Ruizhe Liu, Jianwei Xuan, Sisi Lin, Qiang Zheng, and Jianxin Pang. 2023. “A Cost-Effectiveness Analysis of IGlarLixi Versus IDegAsp and Appropriate Price Exploration of IGlarLixi for Type 2 Diabetes Mellitus Patients in China.” Clinical Drug Investigation 43 (4): 251–63. doi:10.1007/s40261-023-01255-w.